Entering the CNS for fenebrutonib
As Brutons tyrosine kinase is supposed to target B cells and macrophages and macrophages in the brain may be important for progression, it is important to show that there is brain...
As Brutons tyrosine kinase is supposed to target B cells and macrophages and macrophages in the brain may be important for progression, it is important to show that there is brain...
Genentech’s experimental oral therapy fenebrutinib may help control the chronic inflammation in the brain associated with disability progression in both relapsing forms of multiple...
The U.S. Food and Drug Administration (FDA) has agreed to review an application from Roche seeking approval of its BTK inhibitor fenebrutinib as a treatment for relapsing forms of...
The FDA previously hadn’t ever accepted an application of a drug like fenebrutinib in two major forms of MS. But safety questions still hang over Roche’s program.
Weindl et al. Remibrutinib versus teriflunomide in relapsing multiple sclerosis (REMODEL-1 and REMODEL-2): two randomised, phase 3 trials Lancet Online firstOctober 23, 2026Open ac...
INDIANAPOLIS, Oct. 2, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved an additional indication...
The experimental oral therapy remibrutinib significantly reduced relapse rates and brain lesion activity more than the approved therapy Aubagio (teriflunomide) in two Phase 3 clini...
Editor’s note: This is a developing story. Please check back soon for updates.The FDA approved zilurgisertib tablets for the reduction of heterotopic ossification among patients ag...
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.